422 related articles for article (PubMed ID: 7686362)
21. Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia.
Ho PJ; Baxter RC
Clin Endocrinol (Oxf); 1997 Mar; 46(3):333-42. PubMed ID: 9156044
[TBL] [Abstract][Full Text] [Related]
22. [Clinical evaluation of serum prostatic specific antigen in prostatic cancer: simultaneous assays of prostatic specific antigen, gamma-seminoprotein and prostatic acid phosphatase in 113 newly diagnosed patients with prostatic cancer].
Arai Y; Yoshki T; Okada K; Yoshida O; Yamamoto N; Sakatoku J; Sugimura Y; Kawamura J
Hinyokika Kiyo; 1989 Sep; 35(9):1519-28. PubMed ID: 2479237
[TBL] [Abstract][Full Text] [Related]
23. [Prostate-specific antigen. A new biological serum marker for prostatic adenocarcinoma].
Haukaas S; Skaarland E; Halvorsen OJ; Stensland E; Farstad M
Tidsskr Nor Laegeforen; 1990 Sep; 110(23):2990-3. PubMed ID: 1700496
[TBL] [Abstract][Full Text] [Related]
24. Prostate-specific antigen (PSA). A tissue-specific and sensitive tumor marker.
Mulders TM; Bruning PF; Bonfrer JM
Eur J Surg Oncol; 1990 Feb; 16(1):37-41. PubMed ID: 1689677
[TBL] [Abstract][Full Text] [Related]
25. [The value of the serum level of the prostate-specific antigen in prostatic pathology].
Théodon P; Rymer JC; Chopin D; Kouyoudjian JC; Abbou CC; Auvert J
Ann Urol (Paris); 1988; 22(3):199-205. PubMed ID: 2456713
[TBL] [Abstract][Full Text] [Related]
26. Reverse transcriptase polymerase chain reaction for prostate specific antigen in the management of prostate cancer.
Gomella LG; Raj GV; Moreno JG
J Urol; 1997 Aug; 158(2):326-37. PubMed ID: 9224297
[TBL] [Abstract][Full Text] [Related]
27. TPS and CA 15.3 serum values as a guide for treating and monitoring breast cancer patients.
Giai M; Roagna R; Ponzone R; Biglia N; Sgro L; Perona M; Sismondi P
Anticancer Res; 1996; 16(2):875-81. PubMed ID: 8687144
[TBL] [Abstract][Full Text] [Related]
28. The importance of human glandular kallikrein and its correlation with different prostate specific antigen serum forms in the detection of prostate carcinoma.
Recker F; Kwiatkowski MK; Piironen T; Pettersson K; Lümmen G; Wernli M; Wiefelspütz J; Graber SF; Goepel M; Huber A; Tscholl R
Cancer; 1998 Dec; 83(12):2540-7. PubMed ID: 9874461
[TBL] [Abstract][Full Text] [Related]
29. [Anatomoclinical and biologic correlations in prostatic pathology. Apropos of 150 case reports].
Amiel J; Chevallier D; Peyrottes A; Benoliel J; Toubol J
Ann Urol (Paris); 1989; 23(6):528-30. PubMed ID: 2482700
[TBL] [Abstract][Full Text] [Related]
30. [PSA in the staging and monitoring of cancer of the prostate].
Gil Sanz MJ; Sanz Velez JI; Liedana Torres JM; Roncales Badal AL; Allepuz Losa C; Rioja Sanz LA
Actas Urol Esp; 1991; 15(6):527-31. PubMed ID: 1724347
[TBL] [Abstract][Full Text] [Related]
31. Relative reliability of five serially measured markers for prognosis of progression in prostate cancer.
Killian CS; Emrich LJ; Vargas FP; Yang N; Wang MC; Priore RL; Murphy GP; Chu TM
J Natl Cancer Inst; 1986 Feb; 76(2):179-85. PubMed ID: 2418245
[TBL] [Abstract][Full Text] [Related]
32. Immunohistochemical staining and serotest markers during development of a sarcomatoid and small cell prostate tumor.
Frković-Grazio S; Kraljić I; Trnski D; Tarle M
Anticancer Res; 1994; 14(5B):2151-6. PubMed ID: 7840515
[TBL] [Abstract][Full Text] [Related]
33. Prostate cancer progression in the presence of undetectable or low serum prostate-specific antigen level.
Leibovici D; Spiess PE; Agarwal PK; Tu SM; Pettaway CA; Hitzhusen K; Millikan RE; Pisters LL
Cancer; 2007 Jan; 109(2):198-204. PubMed ID: 17171704
[TBL] [Abstract][Full Text] [Related]
34. [Prostatic specific antigen for detection and monitoring of prostatic cancer].
Gofrit O; Pode D; Gez E; Pfau A; Roizman I; Lifshitz Y; Barak V
Harefuah; 1992 Mar; 122(6):345-8, 408. PubMed ID: 1374729
[TBL] [Abstract][Full Text] [Related]
35. Elevated carcinoembryonic antigen in patients with androgen-independent prostate cancer.
Feuer JA; Lush RM; Venzon D; Duray P; Tompkins A; Sartor O; Figg WD
J Investig Med; 1998 Feb; 46(2):66-72. PubMed ID: 9549229
[TBL] [Abstract][Full Text] [Related]
36. [Effects of prostatic massage on serum levels of prostatic acid phosphatase and specific antigen].
Sahin A; Ozen H; Balbay D; Bircan K; Koray Z; Karaagaoglu E; Remzi D
Bull Cancer; 1992; 79(11):1097-100. PubMed ID: 1284587
[TBL] [Abstract][Full Text] [Related]
37. Similar rates of exponential decrease in serum concentrations of free prostate-specific antigen (PSA), PSA complexed to alpha-1-antichymotrypsin, and human glandular kallikrein 2 (hK2) in prostate cancer patients treated with GnRH-analogues.
Björk T; Schalken J; Wittjes W; Ljungberg B; Lilja H
Prostate; 2001 Apr; 47(1):14-20. PubMed ID: 11304725
[TBL] [Abstract][Full Text] [Related]
38. Calculated fast-growing benign prostatic hyperplasia--a risk factor for developing clinical prostate cancer.
Hammarsten J; Högstedt B
Scand J Urol Nephrol; 2002; 36(5):330-8. PubMed ID: 12487736
[TBL] [Abstract][Full Text] [Related]
39. [Tumor markers in prostate cancer].
Kuriyama M
Gan To Kagaku Ryoho; 1994 Sep; 21(12):1915-22. PubMed ID: 7521999
[TBL] [Abstract][Full Text] [Related]
40. [Evaluation of serum tissue polypeptide antigen (TPA) in patients with urogenital cancer].
Tozuka K; Yonese Y; Nakagami Y; Minowa T; Hiraoka Y; Yamada N; Hikima N; Ishii Y; Tannowa K; Fujioka Y
Gan To Kagaku Ryoho; 1984 May; 11(5):1078-83. PubMed ID: 6721513
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
